Safety Study for Patients With a History of Hepatic Encephalopathy

Trial Profile

Safety Study for Patients With a History of Hepatic Encephalopathy

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy
  • Focus Adverse reactions; Registrational
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 29 Apr 2016 Results of a post-hoc analysis published in the Clinical Therapeutics
    • 23 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top